Iovance Q3 product revenue $58.6M; net loss narrows to $0.28/shr; FY24 guidance reaffirmed

IOVANCE BIOTHERAPEUTICS, INC.

2024-Q3 EPS reported -$1.03 revenue$90,376,000

Q3 2024 product revenue $58.6M ($42.1M Amtagvi, $16.5M Proleukin); net loss $83.5M ($0.28/shr) vs $113.8M ($0.46/shr) YoY.
Reaffirms FY24 total product revenue guidance of $160-$165M and FY25 guidance of $450-$475M.
146 patients infused with Amtagvi since Apr 2024 launch; 82 infusions in Q3; 56 ATCs onboarded, targeting 70 by year-end.
Regulatory submissions accepted in EU, UK, Canada; potential approvals in 1H2025 (UK) and 2H2025 (EU, Canada).
Enrollment accelerating in IOV-LUN-202 Phase 2 NSCLC trial; potential accelerated U.S. approval for lifileucel in NSCLC expected in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.